JPRN-jRCT2080221030未知2 期
A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase 2b Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
适应症
试验速览
- 阶段
- 2 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Diagnosis of COPD with symptoms over 1 year
- •- Smokers or ex-smokers
- •- Males or post-menopausal females between 40 and 80 years old
- •- Able to use electronic device
排除标准
- •- Past history or current evidence of clinically significant heart disease
- •- Current diagnosis of asthma
- •- Patients who require long term oxygen therapy
- •- Treatment with antibiotics within 4 weeks of study visit 1b
研究者
相似试验
进行中（未招募）
1 期
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisDiabetic GastroparesisEUCTR2017-002177-20-ATAllergan Ltd.311
进行中（未招募）
1 期
A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007, PT008 and placebo in asthma patients 4 years of age or older (DENALI).Symptomatic AsthmaMedDRA version: 21.0Level: LLTClassification code 10003561Term: Asthma, unspecifiedSystem Organ Class: 100000004855EUCTR2018-003674-27-CZBond Avillion 2 Development LP1,000
进行中（未招募）
1 期
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisDiabetic GastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-002136-16-ITALLERGAN LIMITED2,500
进行中（未招募）
1 期
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisDiabetic GastroparesisEUCTR2017-002177-20-HUAllergan Ltd.2,500
进行中（未招募）
1 期
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersDiabetic GastroparesisEUCTR2017-002136-16-BGAllergan Ltd.2,500